Position in VTRS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Derivatives in VTRS
reported options exposure · as of Mar 31, 2026CallValue
$67,550,000
CallShares
5,000,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Nantahala Capital Management, LLC holds $159,502,303 across 10 Drug Manufacturers - Specialty & Generic names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AMRX |
Amneal Pharmaceuticals, Inc.
|
2,844,108 | $35,352,262 | |
| 2 | ETON |
Eton Pharmaceuticals, Inc.
|
1,175,951 | $29,022,470 | |
| 3 | EOLS |
Evolus, Inc.
|
6,376,857 | $26,208,882 | |
| 4 | ADCT |
ADC Therapeutics SA
|
5,597,433 | $20,990,373 | |
| 5 | BCRX |
Biocryst Pharmaceuticals Inc
|
1,987,397 | $18,920,019 | |
| 6 | ASRT |
Assertio Holdings, Inc.
|
692,335 | $13,195,905 | |
| 7 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
535,684 | $7,446,007 | |
| 8 | AYTU |
Aytu Biopharma, Inc
|
1,086,812 | $2,966,996 |
All Filings in VTRS
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $67,550,000 | 5,000,000 | Call | Sole | 2026-05-15 | |
| 2025-12-31 | $62,250,000 | 5,000,000 | Call | Sole | 2026-02-13 | |
| 2025-09-30 | $49,500,000 | 5,000,000 | Call | Sole | 2025-11-14 | |
| 2025-06-30 | $44,650,000 | 5,000,000 | Call | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||